Reduced expression and defective modulation of TNF receptor/ligand family molecules on proB-ALL blasts

Klinische Padiatrie

Volumn 220, Issue 6, 2008, Pages 353-357

  Troeger, Anja ^a   Glouchkova, L ^b   Escherich, G ^c   Siepermann, M ^a   Hanenberg, H ^a   Janka Schaub, G ^c   Gobel U ^a   Ackermann, B ^a   Dilloo, D ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Pediatrics; ProB ALL; TNF receptors

Indexed keywords

CD40 LIGAND; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANIMAL CELL; APOPTOSIS; ARTICLE; B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOREGULATION; LEUKEMIA REMISSION; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

ADOLESCENT; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; BLAST CRISIS; CHILD; CHILD, PRESCHOOL; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOPHENOTYPING; INFANT; LEUKEMIA, PROLYMPHOCYTIC, B-CELL; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; UP-REGULATION;

EID: 56349088823     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1086028     Document Type: Article

References (28)

1. Armstrong SA, Staunton JE, Silverman LB et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41-47
2. Baryshnikov A, Polosukhina ER, Tupitsin NN et al. CD95 (FAS/APO-1) antigen is a new prognostic marker of blast cells of acute lymphoblastic leukaemia patients. Adv Exp Mecl Biol 1999; 457: 251-258
3. Borkhardt A, Wuchter C, Viehmann S et al. Infant acute lymphoblastic leukemia - combined cytogenetic, immunophenotypical and molecular analysis of 77 cases. Leukemia 2002; 16: 1685-1690
4. Den Boer ML, Harms DO, Pieters R et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 3262-3268
5. Faber J, Armstrong SA. Defining leukemia stem cells in MLL-translocated leukemias: implications for novel therapeutic strategies. Klin Padiatr 2007; 219: 306-311
6. Fulda S, Meyer E, Friesen C et al. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 2001; 20: 1063-1075
7. Gordon J. CD40 and its ligand: central players in B lymphocyte survival, growth, and differentiation. Blood Rev 1995; 9: 53-56
8. Grewal IS, Flavell RA. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 1996; 153: 85-106
9. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000; 14: 2234-2239
10. Holleman A, den Boer ML, Menezes RX de et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood 2006; 107: 769-776
11. Janka-Schaub GE, Harms D, Goebel U et al. Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood - follow up after 9 years. Coall Study Group. Eur J Pediatr 1996; 155: 640-648
12. Law CL, Wormann B, LeBien TW. Analysis of expression and function of CD40 on normal and leukemic human B cell precursors. Leukemia 1990; 4: 732-738
13. Lowdell MW, Lamb L, Hoyle C et al. Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias. Br J Haematol 2001; 114: 11-24
14. Maurer D, Holter W, Majdic O et al. CD27 expression by a distinct subpopulation of human B lymphocytes. Eur J Immunol 1990; 20: 2679-2684
15. Nilsson A, Milito A de, Mowafi F et al. Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. Exp Hematol 2005; 33: 1500-1507
16. Posovszky C, Friesen C, Herr I et al. Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosis. Leukemia 1999; 13: 400-409
17. Prasad KV, Ao Z, Yoon Y et al. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proc Natl Acad Sci USA 1997; 94: 6346-6351
18. Ramakers-van Woerden NL, Beverloo HB, Veerman AJ et al. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia 2004; 18: 521-529
19. Schattner EJ, Elkon KB, Yoo DH et al. CD40 ligation induces Apo-1/ Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med 1995; 182: 1557-1565
20. Schultz KR, Pullen DJ, Sather HN et al. Risk - and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007; 109: 926-935
21. Trentin L, Perin A, Siviero M et al. B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation. Cancer 2000; 89: 1259-1268
22. Troeger A, Glouchkova L, Ackermann B et al. High expression of CD40 on BCP-ALL blasts is an independent risk factor associated with improved survival and enhanced capacity to upregulate the death receptor CD95. Blood 2008; 112: 1028-1034
23. Troeger A, Schmitz I, Siepermann M et al. Up-regulation of c-FLIPS+R upon CD40 stimulation is associated with inhibition of CD95-induced apoptosis in primary precursor B-ALL. Blood 2007; 110: 384-387
24. Troeger A, Siepermann M, Escherich G et al. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica 2007b; 92: 1043-1050
25. Troger A, Siepermann M, Mahotka C et al. Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia. Klin Padiatr 2007; 219: 127-133
26. Hove LE Van den, Gool SW Van, Vandenberghe P et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 1997; 11: 572-580
27. Yellin MJ, Sinning J, Covey LR et al. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994; 153: 666-674
28. Yoon Y, Ao Z, Cheng Y et al. Murine Siva-1 and Siva-2, alternate splice forms of the mouse Siva gene, both bind to CD27 but differentially transduce apoptosis. Oncogene 1999; 18: 7174-7179